A randomized, open-label, two-period, parallel group, crossover study to evaluate the pharmacokinetics of venlafaxine extended-release and DVS [desvenlafaxine] SR in healthy subjects who are extensive or poor cytochrome P450 2D6 substrate metabolizers
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2013
At a glance
- Drugs Desvenlafaxine (Primary) ; Venlafaxine (Primary)
- Indications Depression; Depressive disorders
- Focus Pharmacogenomic; Pharmacokinetics
- Sponsors Wyeth
- 07 Feb 2013 Actual end date Jun 2007 added as reported by ClinicalTrials.gov.
- 18 Oct 2006 New trial record.